Summary
Objectives Safety and immunogenicity assessment of updated monovalent and bivalent SARS-CoV-2 vaccines in adolescents.
Methods This phase 3, double-blinded study randomised 12–<18-year-old participants, who received ≥2 prior doses of an approved/authorised mRNA-based COVID-19 vaccine, 1:1 to receive NVX-CoV2601 (XBB.1.5) or a bivalent vaccine (NVX-CoV2373 [Wuhan] + NVX-CoV2601). The primary immunogenicity endpoint was day-28 neutralizing antibody (nAb) geometric mean titres (GMTs) against XBB.1.5. Safety endpoints were solicited reactogenicity ≤7 days and unsolicited adverse events (AEs) ≤28 days post vaccination and frequency/severity of predefined AEs of special interest through day 180.
Results Of 401 randomised participants, nAb GMTs against XBB.1.5 increased (GMFR [95% CI]) for both NVX-CoV2601 (12.2 [9.5–15.5]) and the bivalent vaccine (8.4 [6.8–10.3]); post-vaccination responses to ancestral SARS-CoV-2 and the JN.1 variant were also observed. Increases in anti-spike IgG levels were comparable between the groups. Solicited and unsolicited AEs were mild to moderate, with similar occurrence among the groups. Severe and serious events were rare and unrelated to the study vaccines; no PIMMCs or myocarditis/pericarditis were reported.
Conclusions NVX-CoV2601 elicited more robust antibody responses to XBB.1.5 and ancestral virus, compared with a bivalent formulation. The safety profile within each group was consistent with the prototype vaccine (NVX-CoV2373).
Competing Interest Statement
CB, GC, JSP, MZ, SCC, ZC, RK, KH, KS, SN, MZ, FN, and RMM are current Novavax, Inc. employees and, as such, receive a work salary and hold Novavax, Inc. stock. EC, LC, JiA, ABH, KP, and JMA are investigators in the 2019nCoV-314 Study. JMA is also an investigator in COVID vaccine studies with GSK, Moderna, Inc., Pfizer Inc., Medicago Inc, and CyanVac LLC.
Clinical Trial
NCT05973006
Funding Statement
Novavax, Inc. funded the 2019nCoV-314 study, provided the vaccine, and collaborated with the investigators on protocol design, data analysis and interpretation, and preparation of this report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The study information is available at https://clinicaltrials.gov/study/NCT05973006. Requests submitted to the corresponding author will be considered upon publication of this article, and deidentified participant data may be provided. The study protocol is available in online supplemental material.
